X

Trial Profile

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Napabucasin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Registrational; Therapeutic Use
Acronyms CanStem111P
Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America

Most Recent Events

05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
15 Aug 2020 This trial has been completed in Belgium (Global date of the end of the trial: 2020-03-29 and Czech Republic).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com